Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies—TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy

Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism

(2021) Melina Verso et al.   EUROPEAN JOURNAL OF CANCER

The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants

(2020) Michal Ariela Raz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

(2020) Giancarlo Agnelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants

(2020) Kevin Hill et al.   JAMA Internal Medicine

Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis

(2019) Daniel Caldeira et al.   PLoS One

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

(2019) Alok A. Khorana et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticoagulation of cancer patients with non‐valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH

(2019) A Aurelien Delluc et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH

(2019) Tzu‐Fei Wang et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

(2019) Nigel S. Key et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study

(2019) Christina Boegh Jakobsen et al.   BMC CANCER

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

(2019) Robert D. McBane et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

(2018) Annie M. Young et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH

(2018) A. A. Khorana et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

(2018) Gary E. Raskob et al.   NEW ENGLAND JOURNAL OF MEDICINE

How I treat cancer-associated venous thromboembolism

(2018) Noémie Kraaijpoel et al.   BLOOD

Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

(2018) Marc Carrier et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies

(2017) J. J. Shatzel et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Drug-drug interactions of non-vitamin K oral anticoagulants

(2016) Christos Voukalis et al.   Expert Opinion on Drug Metabolism & Toxicology

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

(2015) S. Kaatz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions

(2014) M. Levade et al.   BLOOD

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

(2014) S Kamel et al.   LEUKEMIA

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Oral Anticoagulants and the Cancer Patient

(2013) N. J. Short et al.   ONCOLOGIST

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

(2009) Youjin Je et al.   LANCET ONCOLOGY